Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

Clinical Immunology

Volumn 155, Issue 2, 2014, Pages 176-187

  Berkowitz, Jonathan L ^a,d   Janik, John E ^a   Stewart, Donn M ^a   Jaffe, Elaine S ^a   Stetler Stevenson, Maryalice ^a   Shih, Joanna H ^a   Fleisher, Thomas A ^b   Turner, Maria ^a   Urquhart, Nicole E ^c   Wharfe, Gilian H ^c   Figg, William D ^a   Peer, Cody J ^a   Goldman, Carolyn K ^a   Waldmann, Thomas A ^a   Morris, John C ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF THE WEST INDIES   (Jamaica)

^d Sansum Clinic   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Adult T cell leukemia lymphoma; Daclizumab; Human T cell leukemia virus 1 (HTLV 1) associated ATL; Interleukin 2 receptor alpha; Monoclonal antibody

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CREATININE; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ALPHA; POTASSIUM; SODIUM; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHUS OBSTRUCTION; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HEART FAILURE; HUMAN; HYPERCALCEMIA; HYPOKALEMIA; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; KARNOFSKY PERFORMANCE STATUS; LEUKEMIA CELL; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MYALGIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; POTASSIUM BLOOD LEVEL; PROGRESSION FREE SURVIVAL; PSORIASIS; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; T CELL LEUKEMIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; URINARY TRACT INFECTION; URTICARIA; WHEEZING; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; IMMUNOPHENOTYPING; LEUKEMIA-LYMPHOMA, ADULT T-CELL; METABOLISM; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84910096506     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.09.012     Document Type: Article

References (45)

1. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
2. Gallo R.C., Mann D., Broder S., et al. Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:5680-5683.
3. Yoshida M., Miyoshi I., Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:2031-2035.
4. Broder S., Bunn P.A., Jaffe E.S., et al. T-cell lymphoproliferative syndrome associated with human T-Cell leukemia/lymphoma virus. Ann. Intern. Med. 1984, 100:543-557.
5. Tsukasaki K., Hermine O., Bazarbachi A., et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 2009, 27:453-459.
6. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br. J. Haematol. 1991, 79:428-437.
7. Phillips A.A., Shapira I., Willim R.D., et al. A multicenter clinicopathologic experience of HTLV-1 ATLL: a retrospective 15 year review reveals little progress. ASH Annual Meeting Abstracts 2007, 110:3569. (Abstract).
8. Waldmann T.A., Greene W.C., Sarin P.S., et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac monoclonal antibody identifying the human receptor for T cell growth factor. J. Clin. Invest. 1984, 73:1711-1718.
9. Chen J., Petrus M., Bryant B.R., et al. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T cell leukemia. Blood 2010, 116:5948-5956.
10. Waldmann T.A., White J.D., Goldman C.K., et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 1993, 82:1701-1712.
11. Phillips K.E., Herring B., Wilson L.A., et al. IL-2Rα-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Rα interaction. Cancer Res. 2000, 60:6977-6984.
12. Queen C., Schneider W.P., Selick H.E., et al. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:10029-10033.
13. Junghans R.P., Waldmann T.A., Landolfi N.F., et al. Anti-Tac-H, a humanized antibody to the interleukin-2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990, 50. (1495-02).
14. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 1998, 338:161-165.
15. Nashan B., Light S., Hardie I.R., Lin A., Johnson J.R. Daclizumab double therapy study G. reduction of acute renal allograft rejection by daclizumab. Transplantation January 1999, 67:110-115.
16. Nussenblatt R.B., Fortin E., Schiffman R., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7462-7466.
17. Stevens S.R., Ke M.S., Parry E.J., Mark J., Cooper K.D. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the Severity-Weighted Assessment Tool (SWAT). Arch. Dermatol. 2002, 138:42.8.
18. Junghans R.P., Carrasquillo J.A., Waldmann T.A. Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:1752-1757.
19. Koon H.B., Severy P., Hagg D.S., et al. Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk. Res. 2006, 30:190-203.
20. WHO Handbook for Reporting Results of Cancer Treatment 1979, World Health Organization, (Accessed at http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf on October 14, 2010).
21. Hakimi J., Chizzonite R., Luke D., et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J. Immunol. 1991, 147:1352-1359.
22. Rubin L.A., Kurman C.C., Biddison W.E., Goldman N.D., Nelson D.L. A monoclonal antibody 7G7/B6 binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma 1985, 4:91-102.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989, 10:1-10.
24. R project for statistical computing (Accessed at), (on October 4, 2010). http://www.r-project.org.
25. Tsukasaki K., Utsunomiya A., Fukuda H., et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J. Clin. Oncol. 2007, 25:5458-5464.
26. Bazarbachi A., Plumelle Y., Carlos Ramos J., et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 2010, 28:4177-4183.
27. Ekberg H., Mamelok R.D., Pearson T.C., et al. The challenge of achieving target drug concentrations in clinical trials: experience from the symphony study. Transplantation 2009, 87:1360-1366.
28. Li N., Bian H., Zhang J., Li X., Xiaoping L., Xiaoping J., Zhang Y. The Th17/T reg imbalance exists in patients with heart failure with normal ejection fraction and heart failure with reduced ejection fraction. Clin. Chim. Acta 2010, 411:23-24.
29. Webster A.C., Playford E.G., Higgins G., Chapman J.R., Craig J. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst. Rev. 2004, 1. (CD003897).
30. Kirchner V.A., Suszynski T.M., Radosevich D.M., et al. Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation. Transplant. Proc. 2010, 42:2003-2005.
31. Chaudhuri A., Salvatierra J.O., Sarwal M.M. Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allografts. Pediatr. Transplant. 2009, 13:927-932.
32. Kaplan B., West P., Neeley H., et al. Use of low-dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient. Clin. Transpl. 2008, 22:250-253.
33. Sarwal M.M., Vidhun J.R., Alexander S.R., Satterwhite T., Millan M., Salvatierra O.J. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003, 76:1331-1339.
34. Kukita T., Arima N., Matsushita K., et al. Autocrine and/or paracrine growth of adult T-cell leukaemia tumour cells by interleukin 15. Br. J. Haematol. 2002, 119:467-474.
35. Azimi N., Nagai M., Jacobson S., Waldmann T.A. IL-15 plays a major role in the persistence of tax-specific CD8 cells in HAM/TSP patients. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14559-14564.
36. Chen J., Petrus M., Bryant B.R., et al. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T-cell leukemia cells by a paracrine mechanism. Blood 2008, 111:5163-5172.
37. Ju W., Zhang M., Jiang J.K., et al. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 2011, 117:1938-1946.
38. Onimaru Y., Tsukaski K., Murata K., et al. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met. Int. J. Oncol. 2008, 33:697-703.
39. Wynn D., Kaufman M., Montalban X., et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010, 9:381-390.
40. Bielekova B., Richert N., Howard T., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8705-8708.
41. bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5941-5946.
42. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013, 10:55-67.
43. Wuest S.C., Edwan J.H., Martin J.F., et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 2011, 17:U125-U604.
44. Waldmann T.A., White J.D., Carrasquillo J.A., et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995, 86:4063-4075.
45. Kreitman R.J., Wilson W.H., White J.D., et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 2000, 18:1622-1636.